Alkermes plc said Tuesday that favorable phase III data on its long-acting injectable antipsychotic (LAI), aripiprazole lauroxil, will support its filing an FDA new drug application for the investigational schizophrenia treatment in the third quarter, positioning the company to benefit from trends favoring LAIs.